vermilion life sciences ltd
vermilion life sciences ltd Company Information
Company Number
09234116
Next Accounts
Jun 2025
Directors
Shareholders
peninna dollow
stuart dollow
Group Structure
View All
Industry
Other professional, scientific and technical activities (not including environmental consultancy or quantity surveying) n.e.c.
Registered Address
2 eagle house wimbledon, london, SW19 5EF
vermilion life sciences ltd Estimated Valuation
Pomanda estimates the enterprise value of VERMILION LIFE SCIENCES LTD at £152.9k based on a Turnover of £315.7k and 0.48x industry multiple (adjusted for size and gross margin).
vermilion life sciences ltd Estimated Valuation
Pomanda estimates the enterprise value of VERMILION LIFE SCIENCES LTD at £136.3k based on an EBITDA of £42.2k and a 3.23x industry multiple (adjusted for size and gross margin).
vermilion life sciences ltd Estimated Valuation
Pomanda estimates the enterprise value of VERMILION LIFE SCIENCES LTD at £722.5k based on Net Assets of £307.6k and 2.35x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Vermilion Life Sciences Ltd Overview
Vermilion Life Sciences Ltd is a live company located in london, SW19 5EF with a Companies House number of 09234116. It operates in the other professional, scientific and technical activities n.e.c. sector, SIC Code 74909. Founded in September 2014, it's largest shareholder is peninna dollow with a 50% stake. Vermilion Life Sciences Ltd is a established, micro sized company, Pomanda has estimated its turnover at £315.7k with declining growth in recent years.
Upgrade for unlimited company reports & a free credit check
Vermilion Life Sciences Ltd Health Check
Pomanda's financial health check has awarded Vermilion Life Sciences Ltd a 4 rating. We use a traffic light system to show it exceeds the industry average on 4 measures and has 5 areas for improvement. Company Health Check FAQs
4 Strong
1 Regular
5 Weak
Size
annual sales of £315.7k, make it smaller than the average company (£1.8m)
- Vermilion Life Sciences Ltd
£1.8m - Industry AVG
Growth
3 year (CAGR) sales growth of -17%, show it is growing at a slower rate (6.2%)
- Vermilion Life Sciences Ltd
6.2% - Industry AVG
Production
with a gross margin of 24.4%, this company has a higher cost of product (45%)
- Vermilion Life Sciences Ltd
45% - Industry AVG
Profitability
an operating margin of 13.4% make it more profitable than the average company (5.9%)
- Vermilion Life Sciences Ltd
5.9% - Industry AVG
Employees
with 2 employees, this is below the industry average (18)
2 - Vermilion Life Sciences Ltd
18 - Industry AVG
Pay Structure
on an average salary of £49.7k, the company has an equivalent pay structure (£49.7k)
- Vermilion Life Sciences Ltd
£49.7k - Industry AVG
Efficiency
resulting in sales per employee of £157.9k, this is more efficient (£117.4k)
- Vermilion Life Sciences Ltd
£117.4k - Industry AVG
Debtor Days
it gets paid by customers after 166 days, this is later than average (57 days)
- Vermilion Life Sciences Ltd
57 days - Industry AVG
Creditor Days
its suppliers are paid after 39 days, this is slower than average (32 days)
- Vermilion Life Sciences Ltd
32 days - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- Vermilion Life Sciences Ltd
- - Industry AVG
Cash Balance
There is insufficient data available for this Key Performance Indicator!
- - Vermilion Life Sciences Ltd
- - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 7.7%, this is a lower level of debt than the average (52.6%)
7.7% - Vermilion Life Sciences Ltd
52.6% - Industry AVG
VERMILION LIFE SCIENCES LTD financials
Vermilion Life Sciences Ltd's latest turnover from September 2023 is estimated at £315.7 thousand and the company has net assets of £307.6 thousand. According to their latest financial statements, Vermilion Life Sciences Ltd has 2 employees and maintains cash reserves of 0 as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 | Sep 2019 | Sep 2018 | Sep 2017 | Sep 2016 | Sep 2015 | |
|---|---|---|---|---|---|---|---|---|---|
| Turnover | |||||||||
| Other Income Or Grants | |||||||||
| Cost Of Sales | |||||||||
| Gross Profit | |||||||||
| Admin Expenses | |||||||||
| Operating Profit | |||||||||
| Interest Payable | |||||||||
| Interest Receivable | |||||||||
| Pre-Tax Profit | |||||||||
| Tax | |||||||||
| Profit After Tax | |||||||||
| Dividends Paid | |||||||||
| Retained Profit | |||||||||
| Employee Costs | |||||||||
| Number Of Employees | 2 | 2 | 2 | 2 | 1 | ||||
| EBITDA* |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 | Sep 2019 | Sep 2018 | Sep 2017 | Sep 2016 | Sep 2015 | |
|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 188,938 | 182,840 | 202,387 | 2,972 | 3,353 | 334 | 422 | 1,028 | 698 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments & Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debtors (Due After 1 year) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Fixed Assets | 188,938 | 182,840 | 202,387 | 2,972 | 3,353 | 334 | 422 | 1,028 | 698 |
| Stock & work in progress | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Debtors | 144,289 | 126,364 | 90,142 | 259,429 | 160,054 | 74,144 | 200 | 17 | 0 |
| Group Debtors | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Misc Debtors | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash | 0 | 0 | 0 | 0 | 0 | 0 | 23,066 | 32,194 | 23,086 |
| misc current assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total current assets | 144,289 | 126,364 | 90,142 | 259,429 | 160,054 | 74,144 | 23,266 | 32,211 | 23,086 |
| total assets | 333,227 | 309,204 | 292,529 | 262,401 | 163,407 | 74,478 | 23,688 | 33,239 | 23,784 |
| Bank overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bank loan | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Creditors | 25,632 | 32,851 | 51,020 | 68,653 | 54,816 | 34,311 | 19,219 | 22,430 | 22,472 |
| Group/Directors Accounts | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other short term finances | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other current liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total current liabilities | 25,632 | 32,851 | 51,020 | 68,653 | 54,816 | 34,311 | 19,219 | 22,430 | 22,472 |
| loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accruals and Deferred Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| provisions | 0 | 371 | 268 | 565 | 637 | 67 | 84 | 206 | 140 |
| total long term liabilities | 0 | 371 | 268 | 565 | 637 | 67 | 84 | 206 | 140 |
| total liabilities | 25,632 | 33,222 | 51,288 | 69,218 | 55,453 | 34,378 | 19,303 | 22,636 | 22,612 |
| net assets | 307,595 | 275,982 | 241,241 | 193,183 | 107,954 | 40,100 | 4,385 | 10,603 | 1,172 |
| total shareholders funds | 307,595 | 275,982 | 241,241 | 193,183 | 107,954 | 40,100 | 4,385 | 10,603 | 1,172 |
| Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 | Sep 2019 | Sep 2018 | Sep 2017 | Sep 2016 | Sep 2015 | |
|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||
| Operating Profit | |||||||||
| Depreciation | 606 | 608 | 300 | ||||||
| Amortisation | 0 | 0 | 0 | ||||||
| Tax | |||||||||
| Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debtors | 17,925 | 36,222 | -169,287 | 99,375 | 85,910 | 73,944 | 183 | 17 | 0 |
| Creditors | -7,219 | -18,169 | -17,633 | 13,837 | 20,505 | 15,092 | -3,211 | -42 | 22,472 |
| Accruals and Deferred Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Taxes & Provisions | -371 | 103 | -297 | -72 | 570 | -17 | -122 | 66 | 140 |
| Cash flow from operations | |||||||||
| Investing Activities | |||||||||
| capital expenditure | |||||||||
| Change in Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| cash flow from investments | |||||||||
| Financing Activities | |||||||||
| Bank loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Group/Directors Accounts | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Short Term Loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long term loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hire Purchase and Lease Commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other long term liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| share issue | |||||||||
| interest | |||||||||
| cash flow from financing | |||||||||
| cash and cash equivalents | |||||||||
| cash | 0 | 0 | 0 | 0 | 0 | -23,066 | -9,128 | 9,108 | 23,086 |
| overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| change in cash | 0 | 0 | 0 | 0 | 0 | -23,066 | -9,128 | 9,108 | 23,086 |
vermilion life sciences ltd Credit Report and Business Information
Vermilion Life Sciences Ltd Competitor Analysis
Perform a competitor analysis for vermilion life sciences ltd by selecting its closest rivals, whether from the PROFESSIONAL, SCIENTIFIC AND TECHNICAL ACTIVITIES sector, other micro companies, companies in SW19 area or any other competitors across 12 key performance metrics.
vermilion life sciences ltd Ownership
VERMILION LIFE SCIENCES LTD group structure
Vermilion Life Sciences Ltd has no subsidiary companies.
Ultimate parent company
VERMILION LIFE SCIENCES LTD
09234116
vermilion life sciences ltd directors
Vermilion Life Sciences Ltd currently has 1 director, Dr Stuart Dollow serving since Sep 2014.
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Dr Stuart Dollow | England | 63 years | Sep 2014 | - | Director |
P&L
September 2023turnover
315.7k
+15%
operating profit
42.2k
0%
gross margin
24.4%
+3.1%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
September 2023net assets
307.6k
+0.11%
total assets
333.2k
+0.08%
cash
0
0%
net assets
Total assets minus all liabilities
Similar Companies
vermilion life sciences ltd company details
company number
09234116
Type
Private limited with Share Capital
industry
74909 - Other professional, scientific and technical activities (not including environmental consultancy or quantity surveying) n.e.c.
incorporation date
September 2014
age
11
incorporated
UK
ultimate parent company
accounts
Micro-Entity Accounts
last accounts submitted
September 2023
previous names
N/A
accountant
-
auditor
-
address
2 eagle house wimbledon, london, SW19 5EF
Bank
-
Legal Advisor
-
vermilion life sciences ltd Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to vermilion life sciences ltd.
vermilion life sciences ltd Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for VERMILION LIFE SCIENCES LTD. This can take several minutes, an email will notify you when this has completed.
vermilion life sciences ltd Companies House Filings - See Documents
| date | description | view/download |
|---|
